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Abstract
Purpose To investigate and compare the quantitative accura-
cy of 90Y imaging across different generation PET/CT scan-
ners, for the purpose of dosimetry after radioembolization
with resin microspheres.
Methods A strict experimental and imaging protocol was
followed by 47 international sites using the NEMA 2007/
IEC 2008 PET body phantom with an 8-to-1 sphere-to-
background ratio of 90Y solution. The phantom was im-
aged over a 7-day period (activity ranging from 0.5 to
3.0 GBq) and all reconstructed data were analysed at a
core laboratory for consistent processing. Quantitative ac-
curacy was assessed through measures of total phantom
activity, activity concentration in background and hot
spheres, misplaced counts in a nonradioactive insert, and
background variability.
Results Of the 69 scanners assessed, 37 had both time-of-
flight (ToF) and resolution recovery (RR) capability. These
current generation scanners from GE, Philips and Siemens
could reconstruct background concentrationmeasures to with-
in 10 % of true values over the evaluated range, with greater
deviations on the Philips systems at low count rates, and dem-
onstrated typical partial volume effects on hot sphere recov-
ery, which dominated spheres of diameter <20 mm. For
spheres >20 mm in diameter, activity concentrations were
consistently underestimated by about 20 %. Non-ToF scan-
ners from GE Healthcare and Siemens were capable of pro-
ducing accuratemeasures, but with inferior quantitative recov-
ery compared with ToF systems.
Conclusion Current generation ToF scanners can consistently
reconstruct 90Yactivity concentrations, but they underestimate
activity concentrations in small structures (≤37 mm diameter)
within a warm background due to partial volume effects and
constraints of the reconstruction algorithm. At the highest
count rates investigated, measures of background concentra-
tion (about 300 kBq/ml) could be estimated on average to
within 1 %, 5 % and 2 % for GE Healthcare (all-pass filter,
RR + ToF), Philips (4i8s ToF) and Siemens (2i21s all-pass
filter, RR + ToF) ToF systems, respectively. Over the range
of activities investigated, comparable performance between
GE Healthcare and Siemens ToF systems suggests suitability
for quantitative analysis in a scenario analogous to that of
postradioembolization imaging for treatment of liver cancer.
Keywords Yttrium-90 . PET/CT . Quantitative .
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Introduction
Combined PET and CT (PET/CT) imaging of 90Y micro-
spheres is fast becoming part of the routine protocol to
confirm accurate delivery of radionuclide therapy to tu-
mours in the liver after radioembolization. Clinical affir-
mation of the PET/CT imaging technique was first pub-
lished in 2009 [1], and relies on the minute positron
branching ratio (with probability 31.86±0.47×10−6 [2])
as a result of pair production following de-excitation from
the 0+excited state of 90Zr [3]. Since that time its clinical
use has grown steadily, ranging from confirmation of ra-
dionuclide targeting and absence of extrahepatic uptake
[4, 5], to activity quantification for dosimetry [6–11].
Whilst 90Y PET/CT is a desirable tool for assessment
of the efficacy of the radioembolization procedure, there
Table 1 The scanners
contributing data to the study
according to vendor and model
(all scanners equipped with
standard reconstruction
corrections for attenuation, scatter
and random events)
Vendor Model Crystal
material
Additional corrections Number of
scanners
Number of
reconstructions
GE Healthcare Discovery 690, 710 LYSO ToF, RR 9 21
Discovery 600,
Discovery ST (E)
BGO With or without RR 9 16
Discovery RX LYSO – 3 7
Philips Gemini TF LYSO ToF, RR 9 9
Siemens Biograph mCT LSO ToF, RR 19a 28
Biograph (various) LSO With or without RR 19 28
ToF’ time-of-flight, RR’ resolution recovery (point spread function recovery)
a Including two systems with the new continuous bed motion technology
Fig. 1 Transverse CT slice of a phantom showing segmented hot sphere VOIs (white), cold insert ROI, and 60 background ROIs corresponding to each
sphere diameter as described in NEMA NU 2-2007
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is much that is not well understood about the effects of
the physical decay characteristics on the imaging and re-
construction process. This includes the impact of the low
true coincidence counting rate due to the low positron
branching ratio which results in noisy image data. In ad-
dition, such a low true coincidence rate means that the
prompt gamma emissions from the natural 176Lu in
LSO/LYSO crystals of certain PET scanners cannot nec-
essarily be ignored, as is the case with typical PET radio-
nuclides which have true coincidence rates that are orders
of magnitude greater. Furthermore, the large flux of
bremsstrahlung photons from the dominant beta decay
mode of 90Y results in a singles count rate that exceeds
the true coincidence count rate by a large factor, which
was originally thought to have potential for detector sat-
uration when high amounts of 90Y activity are imaged [1],
although this has not been found in more recent investi-
gations (for example [7, 4, 12]). The additional brems-
Table 2 Reconstructions that
contributed to the study
categorized according to ToF and
non-ToF systems from specific
vendors
System Reconstruction
algorithm
Reconstruction
parameters
Filter Correction Number of
reconstructions
GE Healthcare
ToF
3D OSEM MLEM 24 – 72a All-pass
Gaussian
ToF, RR
ToF
ToF, RR
ToF
–
7
2
7
3
2
GE Healthcare
non-ToF
2D OSEM
3D OSEM
MLEM 16 – 64a All-pass
Gaussian
–
–
RR
–
–
–
4
5
2
3f
5
4f
Philips ToF BLOB OS TFb 4i8s
3i33s or 4i33s
– ToF
ToF
2
6
Philips non-ToF 3D RAMLAc – – 1
Siemens ToF 3D OSEM 1i21s
2i21s
3i21s
All-pass
Gaussian
All-pass
Gaussian
All-pass
Gaussian
ToF, RR
ToF, RR
ToF, RR
ToF, RR
ToF, RR
ToF, RR
9
3
4
2
5
5
Siemens
non-ToF
2D OSEM
3D OSEM
MLEM 16 – 84a
‘NETTRUES’d
‘PROMPTS +
RANDOMS’e
–
RR
RR
7
9
12
ToF’ time-of-flight, RR’ resolution recovery (point spread function recovery)
aMaximum likelihood expectation maximization Bequivalent number^=no. of iterations×no. of subsets
b A list mode algorithm that uses spherical (‘blob’-shaped), as opposed to voxel-shaped, basis functions to
enhance signal and suppress noise; the final image is produced through interpolation from overlapping blobs
to voxels, which acts as a filter [35]
c Row-action maximum-likelihood algorithm that operates using a relaxation parameter to control the amount of
correction applied in each iterative update [36]
d The acquisition mode on the Siemens Biograph series that performs direct subtraction of delayed coincidences
event-by-event [37]
e The acquisition mode on the Siemens Biograph series that stores delayed coincidences as a separate acquisition
for subtraction from prompt events at a later time [37]
f Denotes scanners with LYSO crystal material; all other scanners in this category (GE non-ToF) used BGO
material
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strahlung photons and prompt gammas result in a very
high random fraction when imaging 90Y, seen to be in
the order of 80 % at our institution, compared to a typical
FDG scan of 30 – 40 %. Combined with problematic
scatter modelling for such low count data, this typically
results in very noisy true coincidence sinograms following
the subtraction of both scatter and random events, which
will ultimately affect both the qualitative and quantitative
aspect of the reconstruction.
Postradioembolization 90Y PET/CT has the potential
to allow an improved understanding of the absorbed
dose–response relationship on a cancer-specific basis,
information which may be used in the future to tailor
treatments specifically to the individual. In order to es-
tablish a meaningful association between absorbed dose
and response, a large-scale study is necessary, recruiting
significant numbers of patients who are typically not
available from any one site. Such a multicentre trial
relies heavily on the comparability of intersite data,
which relies on the quantitative accuracy and compara-
bility of the imaging equipment itself [13]. The idea of
harmonization of the image acquisition and analysis ap-
proach to establish intersite compatibility for multicentre
trials based on initial phantom studies has been explored
in the literature (for example [14, 15]). Makris et al.
[16] found that the standard NEMA NU-2 image quality
phantom is ideal for intersite testing and looking for
differences in quantitative concentration measures, and
that comparison of the quantitative accuracy of 18F im-
aging is better achieved using an average concentration
measure across a volume, as opposed to a maximum.
Geworski et al. [17] found that errors in FDG standard-
ized uptake value (SUV) measurement (performed by a
single observer) across multisite PET scanners using a
uniformly filled phantom were below 10 % in 15 out of
19 tested scanners (3D imaging), in agreement with the
findings of Park et al. [18] who also derived SUV cal-
ibration values for each system which could be applied
to intersite compatibility of measures, with a maximum
reported variation corresponding to a calibration factor
of 1.24 (i.e. a 24 % variation in measurement). Whilst a
number of phantom studies have been performed with
90Y on current generation scanners [12, 19–23], to date
there are no data to suggest that quantification estimates
from all PET scanners are optimized and accurate (par-
ticularly when compared with known scanner perfor-
mance with FDG), or that they are consistent across
different generations and vendors, so as to offer compa-
rable data in a trial setting.
The objective of this study was to investigate and com-
pare the quantitative accuracy of 90Y PET/CT imaging on
a large number of scanners from multiple sites, with the
specific intention of moving towards a uniform approach
in the setting of a large-scale clinical trial to establish the
absorbed dose– response re la t ionship fo l lowing
radioembolization with 90Y SIR-Spheres microspheres
(Sirtex, Sydney, Australia) for liver cancer. As such, this
report represents the preclinical assessment phase of a
larger collaboration led by The University of Sydney,
The Royal North Shore Hospital, and Sirtex (known as
QUEST—Quantitative Uptake Evaluation in SIR-
Spheres Therapy).
Materials and methods
Data were acquired on a variety of PET scanners
(Table 1) from the major vendors, with a number of
different reconstructions from systems equipped both
with and without time of flight (ToF) and resolution
recovery (RR). Each site followed an identical experi-
mental protocol utilizing the NEMA 2007/IEC 2008
PET Body Phantom (Data Spectrum Corporation, NC),
with a volume of about 10 L containing a Bcold^
(nonradioactive) solid insert (diameter 51 mm) and six
fillable spheres of various diameters (∅ 10, 13, 17, 22,
28 and 37 mm) filled to an approximate eight-to-one
sphere-to-background ratio with 90Y-chloride (YCl3)
provided in a constant specific activity (PerkinElmer,
Waltham, MA).
Each site was required to measure the phantom vol-
ume and the delivered 90Y solution in the departmental
dose calibrator for comparison with the shipping certif-
icate. The entire delivery vial was added to a volume of
1,300 ml, and this solution was used to fill the phantom
spheres, before the reminder of solution was added to
the background compartment, with the addition of
EDTA/DTPA to the contents to prevent the YCl3 stick-
ing to the phantom walls. This allowed an eight-to-one
sphere-to-background ratio, in keeping with the NEMA
NU 2-2007 [24] image quality guidelines, and was
thought to require minimal phantom manipulation and
activity handling at sites. Residual in the vial was esti-
mated through re-measuring the vial in the dose calibra-
tor after reconstitution to the initial volume with water.
Residual in the needle and syringe was taken as
negligible.
Fig. 2 Differences in measured total activity in the FoV with respect to
the expected total activity over all four imaging time points for (a) GE
Healthcare ToF systems (N=21), (b) GE Healthcare non-ToF systems
(N=23), (c) Philips ToF systems (N=8), (d) Philips non-ToF systems
(N=1), (e) Siemens ToF systems (N=28), (f) Siemens non-ToF
reconstructions (N=28, including only ‘PROMPTS + RANDOMS’
mode acquisitions, see explanation in text). Each datum is the mean for
all scanners and the error bars represent one standard deviation (SD) of
the measured values
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Imaging and reconstruction
After filling with [90Y]YCl3 according to the instructions
supplied, the phantom was imaged on days 0, 3, 5 and 7,
during which time the total activity decayed from 3 GBq
to 0.5 GBq, thus covering the recommended activity
range for therapy prescribed in the SIR-Spheres package
insert formula. This was done to assess scanner perfor-
mance under different rates of photon fluence, and to
assess the impact of background radiation from 176Lu
present in current generation (LSO/LYSO) detector crys-
tals at lower counting rates. Imaging consisted of two
overlapping bed positions to mitigate the triangular axial
sensitivity profile of the scanner, each of 15 – 20 min
duration, in 3D mode. Where 90Y was not available as a
radionuclide selection in the acquisition software a long-
lived isotope was selected (e.g. 22Na) to avoid any scan-
ner decay correction and data were quantified after re-
construction by taking into account the ratio of the pos-
itron branching ratios of 90Y and the acquisition radio-
nuclide. No additional sensitivity measures were
required.
Sites were encouraged to use reconstruction parame-
ters that had proven successful in their own 90Y expe-
rience, with all available corrections (scatter, attenuation,
random coincidences, ToF and RR where available).
Following day 7 of imaging a radiographic contrast
agent was added to the background compartment of
the phantom and a CT study performed to aid in image
segmentation for volume definition of the fillable
spheres.
Image analysis
Data were transferred in DICOM format via a secure data
server (ABX-CRO Advanced Pharmaceutical Services,
Dresden, Germany) to the core laboratory in Sydney
(Royal North Shore Hospital, Sydney, Australia) for con-
sistent analysis. All analyses were performed by a single
operator (K.W.) on a dedicated nuclear medicine worksta-
tion (HERMES; Nuclear Diagnostics, Stockholm,
Sweden) using in-house software written in IDL (Exelis
Visual Information Solutions, Boulder, CO). For the quan-
titative assessment the shipping certificate indicating the
amount of 90Y in the initial vial as determined by the
supplier was treated as the gold standard, and the fraction
of residual measured in the vial during the experimental
procedure was regarded as the total residual (possible re-
sidual in the syringe, needle, beaker etc. was considered
negligible due to the difficulty in reliable measurement of
90Y in the dose calibrator). These measures, together with
measured phantom volume, were used to derive the true
concentration and activity in the phantom at each imaging
time-point. The uncertainty in ‘true’ estimates of activity
and concentration in the phantom was taken to be ±10 %,
a combination of possible volume measurement error
(<1 %) and uncertainty in the calibration of activity in
the delivery vial.
The coregistration of the reconstructed PET data from
all imaging days with the contrast-enhanced CT study
was confirmed and the CT data were used to segment
the six fillable spheres as 3D volumes of interest
(VOIs) using a semiautomated region-growing algorithm
to delineate the physical sphere volume. Quantitative ac-
curacy was assessed at each imaging time-point by mea-
surement of:
– Total activity in the reconstructed field of view (FoV) as
an indicator of total injected activity.
– Background concentration, following the NEMA NU 2-
2007 guidelines (Fig. 1).
– Mean concentration for each of the CT-defined spherical
VOIs (Fig. 1) and the associated recovery coefficient
(RC) to assess partial volume effects (PVEs) on the day-
0 data, defined as:
RC %ð Þ ¼ MeasuredConcentration
TrueConcentration
 100 ð1Þ
Lines of best fit (y=100−ae(−bx)) for recovered concentra-
tion were compared with the curve obtained from repetition of
an identical phantom procedure using 18F (Siemens mCT
Biograph PET/CT, 3i21s 5-mm gaussian RR + ToF) proc-
essed in an identical manner to the experimental 90Y data to
generate reference RCs.
The change in recovery of the largest diameter hot sphere,
least affected by PVEs, over the range of imaging days was
assessed for consistency of recovery with deteriorating count
statistics.
– Counts incorrectly misplaced in the central cold insert,
assessed as the mean of counts in a central ROI replicated
across five transverse slices (Fig. 1) as a percentage of
true background concentration.
– Background variability (BV), in keeping with the
recognized NEMA NU 2-2007 measure of image
quality, was also explored as an indication of po-
tential variation in background concentration mea-
sures as a result of poor image signal-to-noise
Fig. 3 Differences inmeasured background concentrationwith respect to
the true background concentration for (a) GEHealthcare ToF systems, (b)
GE Healthcare non-ToF systems, (c) Philips ToF systems, (d) Philips
non-ToF systems, (e) Siemens ToF systems, (f) Siemens non-ToF
systems (where +RAN and -RAN correspond to data acquired in
‘PROMTS + RANDOMS’ and ‘NETTRUES’ mode, respectively, and
where -RAN was normalized for analysis)
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ratio, defined as:
BVs ¼ STDEVB;sCB;s ð2Þ
whereCB,s is the average of the 60 background ROI counts for
sphere size s, and STDEVB,s is the standard deviation of the
background ROI counts for sphere size s.
Given the number of contributing scanners and variations
in submitted reconstruction parameters, analysis of the data
was stratified by averaging the results according to the cate-
gories listed in Table 2.
Validation of methodology
At one site three consecutive scans were performed on the
same phantom with the same scanner (Siemens mCT
Biograph) using identical image acquisition and recon-
struction parameters. Consistency in the above measures
between the three scans was assessed to indicate uncer-
tainty that might be expected due to random noise and
variations. Furthermore, at a single site a lengthy 8-h ac-
quisition (GE Healthcare Discovery 690, 90Y acquisition
isotope) of the phantom was performed in addition to the
standard 40-min acquisition, the data from which were
used to look for any improvements with increased count
statistics.
In addition, two datasets—one phantom study with
18F (to act as a reference, performed on a Siemens
Biograph mCT, reconstructed using 3i21s ToF + RR
and a 5-mm gaussian filter) and one phantom study with
90Y (performed on a GE Healthcare Discovery 690,
quantified by the scanner, (i.e. performed with 90Y as
the acquisition isotope, and reconstructed with 3i18s
ToF and an all-pass filter)—were analysed by a physicist
at an independent institution not involved in the study.
Background concentration and hot sphere concentrations
and recovery were measured using the following three
software packages for comparison with the in-house
QUEST method:
Method (a) An in-house ImageJ plug-in (NIH, Bethesda,
MD) that uses NEMA guidelines to measure
background concentration and the mean of a
50 % threshold-generated VOI to measure hot
sphere recovery [25].
Method (b) Software provided as part of the European
Association of Nuclear Medicine Research
Ltd (EARL) initiative for standard image qual-
ity assessment of background concentration
and hot sphere recovery as measured through
threshold-derived VOIs on the central slice of
the PET images [26].
Method (c) The ROVER package (ABX-CRO Advanced
Pharmaceutical Services, Dresden, Germany)
which again applies a 50 % growing algorithm
to generate a VOI for hot sphere recovery mea-
surement, and measures background concentra-
tion as the mean of two generated background
VOIs, all of which are manually placed by the
user.
Results
A total of 47 centres from 13 countries contributed data to the
study. The average total activity in the phantom at the first
imaging time-point was 3.26 GBq, with a standard deviation
of 0.26 GBq (8 %).
Dose calibrator measures
The average absolute difference between an individual
site’s measured 90Y activity in the delivery vial in the
local dose calibrator and the vendor-supplied calibration
certificate, decay-corrected to the same time-point, was
5 %, with a measured range of −4 – +25 %, and a median
of +2.5 %.
Quantitative assessment
The accuracy of total activity measured in the FoV and the
measured concentration of activity in the phantom back-
ground at each imaging time-point are shown in Figs. 2
and 3, respectively. Values are expressed as the percent-
age difference between the measured and expected values,
where each measured value is the mean for a given cate-
gory (note that the number of measured data that underlies
these measured values does vary between scanner and
reconstruction methods). The standard deviations of mea-
sures are shown as error bars (thus representing the com-
bined inter-site variability and measurement error at con-
sistent reconstruction parameters) and a general ±10 %
to le rance i s represen ted by the shaded reg ion
Fig. 4 Lines of best fit (y=100−ae(−bx)) for recovered concentrations in
hot spheres of various diameters on day-0 imaging for (a) GE Healthcare
ToF systems (R2=0.94 – 0.98), (b) GEHealthcare non-ToF systems (R2=
0.90 – 0.99), (c) Philips ToF systems (R2=0.97 – 0.98), (d) Philips non-
ToF systems (R2=0.90 – 0.96), (e) Siemens ToF systems (R2=0.80 –
0.99), (f) Siemens non-ToF systems (R2=0.94 – 0.97) (where +RAN
and -RAN correspond to data acquired in ‘PROMTS + RANDOMS’
and ‘NETTRUES’ mode, respectively, and where -RAN was
normalized for analysis). The black line of reference is the recovery
curve for 18F derived from the same experiment
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(representing expected uncertainty in ‘true’ values). For
the Siemens non-ToF systems, only ‘PROMPTS +
RANDOMS’ mode acquisitions were included (Fig. 2f)
because acquisitions in ‘NETTRUES’ mode resulted in
extremely large overestimates when quantification was
performed through rescaling of the acquisition branching
ratio, and the reconstructed data were therefore normal-
ized to the actual total activity in the phantom, such that
estimates of total activity were not meaningful. Despite
this post hoc normalization approach not being ideal in
a clinical scenario (due to the difficulty in measuring re-
sidual in the delivery apparatus and the potential for stasis
to be reached during treatment), it was explored for com-
parison purposes in this controlled phantom study.
Current generation GE Healthcare and Siemens ToF
systems with RR and an all-pass filter produced accept-
able estimates (within ±10 %) of total activity and back-
ground concentration over the range 0.5 – 3 GBq and
50 – 300 kBq/ml, respectively, with improvements seen
in Siemens systems when reconstructing with two or three
iterations. No evidence of detector saturation was seen, in
agreement with the literature [10, 12, 19, 20]. The non-
ToF Siemens systems gave accurate estimates of back-
ground concentration when acquired in ‘PROMPTS +
RANDOMS’ mode. Both BGO and LYSO non-ToF GE
Healthcare systems showed similar behaviour, including
overestimates of activity at levels below 1.5 GBq and
estimates of background above 100 kBq/ml within
15 %. Philips Gemini ToF systems appeared to underesti-
mate total activity at levels below 3 GBq and background
concentrations below 300 kBq/ml, whilst large overesti-
mates across the entire range were seen on the 3D
RAMLA reconstruction. For high activity levels (about
3 GBq) in the FoV, all scanners were capable of produc-
ing satisfactory estimates, presumably due to the im-
proved count statistics which allowed improved scatter
modelling and reduced effect of randoms subtraction.
Recovery of activity concentration measured in the hot
spheres on day 0 of imaging is shown in Fig. 4, and the
change in this recovery for the 37-mm diameter hot
sphere over different days of imaging in Fig. 5. All ToF
systems demonstrated comparable recovery of concentra-
tion in hot spheres (note that at this day-0 imaging time-
point these reconstructions also had comparable measures
of background concentration), and in all cases this was
inferior to that achieved with 18F. Postreconstruction
gaussian filtering resulted in a decrease in recovery due
to smoothing of the activity concentration outside the geo-
metrical volume. All systems demonstrated a steady de-
cline in both 90Y and 18F recovery for spheres with a
diameter below 37 mm due to PVE. The Siemens ToF
reconstructions with two or three iterations were again
superior to a single iteration. Whilst Siemens non-ToF
data acquired in ‘PROMPTS + RANDOMS’ mode dem-
onstrated improvement over ‘NETTRUES’ mode, with
recovery similar to the GE Healthcare non-ToF recon-
structions, the non-ToF systems generally achieved poorer
recovery. All 90Y data suffered from underestimates in the
range of 10 – 20 % of the true activity concentration of
even the largest volume sphere (∅ 37 mm), a finding
consistent with independent analyses of data (see
Fig. 8). In ToF systems recovery underestimates for the
largest hot sphere over all days of imaging gradually de-
teriorated (Fig. 5). This may have been due to the influ-
ence of the 176Lu present in the detector crystals, which
has been suggested to affect low count studies [19]. Non-
ToF systems demonstrated some variation, with a slightly
better recovery with the BGO system and RAMLA at
lower concentrations, which may have been due to dete-
riorating noise and associated spurious high counts in
voxels.
The activity concentrations measured in the cold insert
are displayed as percentages of true background concen-
trations on different days of imaging in Fig. 6. All ToF
systems exhibited similar behaviour (on average about
30 % of background) and in general non-ToF systems
measured far greater scattered events in the cold insert
(on average about 60 % of background). For the GE
Healthcare non-ToF systems this was reduced in BGO
scanners, perhaps due to the absence of background
counts from the natural 176Lu in the crystals.
Figure 7 shows the BV measured on day 0 using re-
gions of various diameters corresponding to the diameters
of each hot sphere. As expected, BV was improved with
postreconstruction gaussian filtering and deteriorated with
increasing numbers of iterations and associated noise. The
ToF systems from all three vendors displayed similar be-
haviour, with slightly better data from the Philips system
perhaps due to the noise suppression properties of the
BLOB OS TF algorithm. The non-ToF GE Healthcare
BGO systems displayed significantly poorer results than
their LYSO counterparts. This may have been due to the
larger coincidence timing window associated with BGO,
which increases the random coincidence rate and may
further increase noise in the reconstructed images.
As a measure of repeatability, the standard deviations
between quantitative measures from three consecutive
Fig. 5 Lines of best fit (y=a+bx) for recovered concentrations in the
largest hot sphere at different concentrations for (a) GE Healthcare ToF
systems (R2=0.54 – 0.87), (b) GE Healthcare non-ToF systems (R2=
0.31 – 0.93), (c) Philips ToF systems (R2=0.55 – 0.88), (d) Philips non-
ToF systems (R2=0.47), (e) Siemens ToF systems (R2=0.21 – 0.75), (f)
Siemens non-ToF systems (R2=0.77 – 0.99) (where +RAN and -RAN
correspond to data acquired in ‘PROMTS + RANDOMS’ and
‘NETTRUES’ mode, respectively, and where -RAN was normalized for
analysis)
Eur J Nucl Med Mol Imaging (2015) 42:1202–1222 1211
1212 Eur J Nucl Med Mol Imaging (2015) 42:1202–1222
scans with an identical phantom, acquisition and recon-
struction protocol are shown in Table 3. The total mea-
sured activity remained constant and a change in mea-
sured concentration in the order of 10 % was seen. The
change in quantitative measures with the 8-h acquisition
(single bed position) was within 10 % of that with the
standard 40-min (two bed positions; Table 3), except for
measures of misplaced events in the cold insert, where the
improved counting statistics increased the cold contrast
ratio by 20 %. This may have been due to better estimates
of scatter prior to subtraction.
Comparison of the QUEST methodology with inde-
pendent analysis using other software for a sample 18F
and 90Y dataset are given in Table 4 for measures of
background concentration and in Fig. 8 for measures of
hot sphere recovery. All methods performed consistently
when measuring both 18F and 90Y concentration data and
demonstrated similar trends in underestimation in recov-
ery curves. The ROVER package, method (c), produced
slightly different measures of background concentration,
most likely due to the use of a large VOI as opposed to
multiple ROIs, and minor variations in recovery curves
can be attributed to the method of VOI generation.
Discussion
It should be recognized that findings regarding scanner
performance discussed in this work are not applicable to
18F imaging, only 90Y, and as such are not a reflection of
scanner behaviour for the vast majority of clinical PET
applications. Comparable and efficient scanner perfor-
mance has been reported in the literature for qualitative
and quantitative 18F imaging aspects for all vendors for
example [27–29]).
The experimental protocol was chosen to cover a clin-
ically realistic range of activities for resin microspheres,
where a standard administration of 90Y SIR-Spheres for
radioembolization is of the order of 1.6 GBq [30]. Given
the diversity in ‘typical’ liver size and tumour burden,
nonuniform deposition of microspheres, and the large dif-
ferences in tumour targeting result ing from the
superselective radioembolization procedure, pinpointing
a representative concentration in background and hot
spheres of the phantom to correspond to patient liver
and tumour uptake is not straightforward. The literature
expresses large differences in this respect, with tested
sphere-to-background ratios ranging from 3:1 [19, 31] to
40:1 [12], and associated background concentrations from
as low as 37 kBq/ml to as high as 470 kBq/ml [20]. Given
the larger volume of the phantom compared to a human
liver, a clinical scenario is thought to lie towards the
higher end of the count spectrum explored in this study.
The achievable measures of total activity to within
10 % of expected values when using optimized recon-
struction parameters on two out of three tested types of
ToF systems implies the suitability of clinical 90Y PET for
confirmation of delivered activity after radioembolization.
This may be particularly useful when stasis is reached
during administration, before the entire prescribed amount
of microspheres has been implanted. This is also true of
background activity concentration measures, which trans-
lates to absorbed dose estimates in nontarget liver.
However, Fig. 6 implies that 20 – 40 % of this back-
ground level could be measured in adjacent true cold re-
gions, which may lead to overestimation of absorbed dose
in healthy liver regions that are devoid of any activity
deposition. The difficulty in determining the existence of
scatter and noise in reconstructed 90Y PET data versus
true nontarget activity deposition in background regions
was investigated by Kao et al. [5], with recommendation
for qualitative assessment to rely on the pattern of uptake
and conformation with underlying anatomy for extrahe-
patic queries, as opposed to relying on visual intensity.
Figures 2 and 3 highlight an apparent difference in
behaviour between ToF systems from the different ven-
dors. During discussions with the vendor Philips, it was
suggested that the large underestimates at low count rates
seen in the Gemini ToF reconstructions may have been
due to the scatter correction algorithm used. Specifically,
the magnitude of the scatter component may be
underestimated at low count rates due to the fact that
any negative pixels in the scatter subtracted sinogram
are zeroed prior to subtraction (positivity constraint on
the reconstruction algorithm), as demonstrated in the
RAMLA reconstructed data (Fig. 3d). The current gener-
ation Philips ToF systems use the same approach to ap-
proximate the final scatter estimate which is then incor-
porated into list mode iterative reconstruction. As such, at
the last iteration of ToF reconstruction, the scatter is esti-
mated from the scatter under-corrected emission data
(RAMLA results), resulting in an erroneously high scatter
contribution, and hence leading to lower ToF emission
counts at these low count rates. It should be noted that
successful quantification of 90Y on Philips ToF PET scan-
ners has been demonstrated in the literature, using a dif-
ferent approach to quantification that relies on a measured
Fig. 6 Measured activity concentrations in the cold insert as percentages
of the true background concentrations at different concentrations for (a)
GE Healthcare ToF systems, (b) GE Healthcare non-ToF systems, (c)
Philips ToF systems, (d) Philips non-ToF systems, (e) Siemens ToF
systems, (f) Siemens non-ToF systems (where +RAN and -RAN
correspond to data acquired in ‘PROMTS + RANDOMS’ and
‘NETTRUES’ mode, respectively, and where -RAN was normalized for
analysis). This measure predominantly reflects the accuracy of scatter and
randoms corrections
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scanner-specific sensitivity factor [22]. This approach
may be desirable on a single-site basis, but for the pur-
pose of this work (as a precursor to a multicentre evalu-
ation) it was not an ideal method due to the need for
additional experimental work and the inability for all sites
to have an identical approach to quantification.
There is an evident difference in both image quality
and quantification when comparing scanners with and
without ToF and RR. There is also a consistent underes-
timation in all quantitative measures in hot spheres, seen
even at long acquisition times (Table 3), and under cir-
cumstances of accurate background quantification. This is
most likely related to the excessive random and scatter
events and low count rates when imaging 90Y, and the
way in which the reconstruction algorithm deals with this,
and is not evident for 18F data which benefits from a true
count rate that is orders of magnitude greater than that of
90Y. Iterative reconstruction algorithms recover low fre-
quency or background events first, implying that higher
iterations are needed for accurate recovery of small hot
objects. However, given the noise and low signal present
in 90Y PET, higher iterations are not a practical solution,
and this is demonstrated in Fig. 4 by the lack of an obvi-
ous improvement with an increasing number of iterations,
and is in agreement with the literature [12, 20, 32].
Furthermore, a longstanding problem in PET recon-
struction is the bias introduced by the necessity to remove
negative sinogram values (which become zeroed) follow-
ing correction for random coincidences, in order to satisfy
the assumption of a Poisson distribution which is the basis
for expectation-maximization-based reconstructions, such
as OSEM. This bias does not have a significant impact for
the vast majority of clinical PET scanning. In the case of
90Y where extremely low count rates are observed in the
setting of high random coincidences, the bias becomes
greater. In contrast, it is known that as the fraction of
random coincidences increases, the gain in signal to noise
ratio associated with ToF increases [33], implying that
current generation scanners that employ ToF would be
more suited to imaging 90Y than previous generation
scanners, an assumption that seems to be verified by these
results. In addition, it is known that iterative reconstruc-
tion converges faster with the use of ToF [27]. These
findings are also supported by other publications [12,
19, 34].
The importance of the treatment of random coinci-
dences is well demonstrated in the Siemens data. The
significant differences in quantification between non-ToF
acquisitions in ‘PROMPTS + RANDOMS’ mode versus
‘NETTRUES’ mode is due to the fact that the latter per-
forms direct subtraction of delayed coincidences event-
by-event, as opposed to storing the separate acquisition
of delayed coincidences that allows smoothing prior to
subtraction from the prompt events. Direct subtraction
without smoothing is more likely to result in false-
negative values in the sinogram, which when reconstruct-
ed using the positivity constraint applied in OSEM algo-
rithms creates noisy data and inaccurate quantification.
The GE Healthcare systems employ the single-event
based method of randoms correction (calculating the
mean random coincidence rate for each line of response
based on the coincidence timing window and the single
photon event rate) and the non-ToF GE Healthcare
Fig. 7 Background variability for different region diameters for (a) GE
Healthcare ToF systems, (b) GE Healthcare non-ToF systems (note
different scale on the y-axis), (c) Philips ToF systems, (d) Philips non-
ToF systems, (e) Siemens ToF systems, (f) Siemens non-ToF systems
(where +RAN and -RAN correspond to data acquired in ‘PROMTS +
RANDOMS’ and ‘NETTRUES’ mode, respectively, and where -RAN
was normalized for analysis)
Table 3 Standard deviations between quantitative measures from
identical processing of three consecutive scans performed on a Siemens
mCTscanner (as percentages of true values), and the differences between
quantitative measures from identical reconstructions of consecutive scans
of 40-min duration and 8-h duration on a GE Healthcare Discovery 690
system (as percentages of those measured in the 8-h acquisition)
Measure Standard deviation
between three
consecutive scans (%)
Difference between
40-min and 8-h
acquisition (%)
Total activity 0.14 –a
Background
concentration
13 −6
Cold region counts 10 +20
Recovery
37-mm sphere 5 +3
28-mm sphere 4 +3
22-mm sphere 8 −3
a Entire phantom not in FoV
Table 4 Differences between measured and true values of background
concentration for each of the analysis methods, represented as
percentages of the true values
Method Difference between measured
and true background concentration (%)
18F 90Y
QUEST 9.9 5.1
Method (a) 9.9 3.9
Method (b) 9.8 1.9
Method (c) 6.6 11.3
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systems do not exhibit the same extreme underestimates
as seen in the non-ToF Siemens systems prior to the use
of smoothing. Furthermore, scatter correction in low
count studies may well be less accurate due to the diffi-
culty of estimating scatter from such noisy sinograms,
evident in the Philips data, and as suggested by van
Elmbt et al. [19], may be further affected by additional
signal coming from pair production in the LSO/LYSO
crystals. The cumulative effect is a remarkable improve-
ment in the ability of current generation scanners to image
and quantify 90Y.
Results suggest that previous generation scanners with-
out RR and ToF do not produce consistent quantitative
90Y measures for comparison with current generation
scanners. From the range of data investigated in this
study, 90Y imaging performance appears to be optimal
for Siemens systems using two iterations and 21 subsets
with ToF and RR for best quantification without
compromising measures affected by noise, with an all-
pass filter (or with a 5 – 8 mm gaussian filter for qualita-
tive purposes). For GE Healthcare systems the use of an
all-pass filter in conjunction with RR and ToF gave the
most consistent results for quantification, and a subset
analysis of data (not shown) suggested two iterations
and 24 subsets. Investigation of the Philips ToF recon-
structions of 90Y is ongoing, including communication
Fig. 8 Recovered concentrations for hot spheres of various diameters using four software analysis methods for both 18F data (a) and 90Y data (b)
Table 5 Reconstruction parameters that provided most accurate
quantification over the assessments performed in this investigation, and
the expected accuracy and standard deviations associated with measures
of warm background and hot spheres for each. All measures are based on
the results from day-0 imaging, where phantom background and hot
sphere concentration were about 300 kBq/ml and 2,500 kBq/ml,
respectively
Vendor Model Recommended reconstruction
for quantitative purposes
Error in warm background
concentration measures (%)
Error in 37-mm hot sphere
concentration measures (%)
Average±SD Range Average±SD Range
GE Healthcare Discovery 600 Discovery
ST (E) Discovery RX
3D OSEM with all-pass filter:
e.g. 2i24s
−9±10 +4 – 29 −34±9 −14 – 49
GE Healthcare Discovery 690 Discovery 710 3D OSEM with all-pass filter:
e.g. 2i24s + RR + ToF
1±4 +6 – 7 −14±9 −5 – 28
Philips Gemini TF 3D OSEM (BLOB OS TF) with
no filter: 4i8s + ToF
−5±2 −4 – 6 −22±3 −20 – 24
Siemens Biograph (various) 3D OSEM with all-pass filter:
e.g. 2i21s + RR (acquired in
‘PROMPTS + RANDOMS’ mode)
2±9 +9 – 22 −27±5 −20 – 40
Siemens Biograph mCT 3D OSEM with all-pass filter:
2i21s + RR + ToF
−2±6 +4 – 9 −16±4 −13 – 22
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with the vendor, but at present total measures of activity
and concentration in background regions may be
underestimated for low concentration regions.
In the imaging of 90Y for quantitative purposes with
non-ToF generation GE Healthcare and Siemens scanners,
measures of large areas of concentration (about 300 kBq/
ml) can be expected, on average, to be within 9 % and
2 % of true values, respectively, but recovery of concen-
tration measures in hot lesions (about 2,500 kBq/ml) can
be expected to be inferior to imaging with their ToF coun-
terparts, with average underestimates of −34 % and
−27 %, respectively, for a 37-mm diameter object (see
Table 5 for complete comparison). A different analysis
method, such as a threshold-based VOI, may improve
these RCs, but given the very noisy nature of the 90Y
reconstructions this may also be affected by a spurious
maximum value. This study suggests that with Siemens
non-ToF scanners, data should not be acquired in
‘NETTRUES’ mode if correct quantification of 90Y is
desired, and the most consistently accurate results were
seen when using ‘PROMPTS-RANDOMS’ mode with
two iterations and 21 subsets in combination with RR.
A ±10 % uncertainty can be expected on quantitative
measures due to random noise in the acquisition and re-
construction process, which is approximately consistent in
regions of non-zero background activity and hot spots
(Table 3). Coupled with the uncertainty in the 90Y activity
(±10 %) treated as the gold standard in this work, quan-
titative measures on ToF PET systems with the recon-
structions discussed can be expected to produce accept-
able estimates of activity and concentration in large ho-
mogeneous areas over a clinically realistic range of
values. It should be expected that hot lesion quantification
(and so absorbed dose estimates) may be underestimated
with all current generation scanners to a consistent degree
of 15 – 20 % for a 37-mm diameter object. Such under-
estimates may be improved with a different volume defi-
nition technique, as explored by Goedicke et al. [22].
Given the lack of significant improvement in warm and
hot volume quantification with increased acquisition du-
rations (Table 3), a 40-min acquisition is recommended in
the clinical setting, acquired as two bed positions (20 min
each) to avoid the area of interest (liver) imposing on the
edges of the FoV where noise is greatest in the recon-
structed data, and to avoid peaking of the scanner’s sen-
sitivity profile.
Conclusion
In summary, current generation ToF PET scanners are ca-
pable of producing comparable quantification of 90Y over
a large range of clinically realistic activity and concentra-
tion levels. In terms of quantitative accuracy of estimates
and expected uncertainties for translation to clinical mea-
sures of absorbed dose, Table 5 shows the average errors
and ranges of measures for those reconstructions that were
found to be best, based on the data investigated in this
work. Considering possible acceptance criteria for scan-
ners acquiring data in a clinical trial setting, an achievable
accuracy of concentration measures in large uniform re-
gions of activity of 10 % (average) over a range of clin-
ically realistic true concentrations (50 – 300 kBq/ml) may
be considered suitable performance.
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